Access cutting-edge cholangiocarcinoma treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.
Access cholangiocarcinoma specialists in Dallas at no cost
This study follows strict safety protocols and ethical guidelines
All study-related cholangiocarcinoma treatment provided free
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
Sponsor: Taiho Oncology, Inc.
Check if you qualify for this cholangiocarcinoma clinical trial in Dallas, TX
If you're searching for cholangiocarcinoma treatment options in Dallas, TX, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cholangiocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.